Targeting mTOR-CCL20 Signaling May Improve Response to Docetaxel in Head and Neck Squamous Cell Carcinoma

Targeting mTOR-CCL20 Signaling May Improve Response to Docetaxel in Head and Neck Squamous Cell Carcinoma

Patients with advanced head and neck squamous cell carcinoma (HNSCC) usually show a dismal prognosis. It is this worthwhile to develop new, effective therapeutic regimens for these patients, such as molecular targeted therapy, which is promising as an alternative or combination treatment for HNSCC....

Full description

Bibliographic Details
Main Authors: Ming-Huei Chou, Hui-Ching Chuang, Yu-Tsai Lin, Ming-Hsien Tsai, Ying-Hsien Kao, I-Chun Lin, Tai-Lin Huang, Fu-Min Fang, Chih-Yen Chien
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:International Journal of Molecular Sciences
Subjects:
head and neck squamous cell carcinoma
mTOR-CCL-20
docetaxel
rapamycin
BEZ235
Online Access:https://www.mdpi.com/1422-0067/22/6/3046

Internet

https://www.mdpi.com/1422-0067/22/6/3046

Similar Items